Dosages for botluinum toxins are not interchangeable says study

28 Feb 2012

Allergan recently unveiled new data from a multicenter, randomised, double-blind trial that showed 20 Units of VISTABEL® was as effective as 30 Units of Bocouture® for the treatment of moderate to severe glabellar lines. The study results were presented during the 7th European Masters in Anti-Ageing Medicine (EMAA) congress in Paris. “This new study underlines why it is important that medical aesthetic practitioners are aware of the differences between each of the botulinum toxins when selecting the most appropriate treatment for their patients,” comments Dr Moers-Carpi from Munich, Germany and lead investigator for the study. “With botulinum toxin manufacturers each having unique definitions of a unit, aesthetic practitioners should be vigilant in adopting the treatment protocol set by the respective manufacturer and not translating previous experience with one toxin to another.”

Allergan recently unveiled new data from a multicenter, randomised, double-blind trial that showed 20 Units of VISTABEL® was as effective as 30 Units of Bocouture® for the treatment of moderate to severe glabellar lines. The study results were presented during the 7th European Masters in Anti-Ageing Medicine (EMAA) congress in Paris.
“This new study underlines why it is important that medical aesthetic practitioners are aware of the differences between each of the botulinum toxins when selecting the most appropriate treatment for their patients,” comments Dr Moers-Carpi from Munich, Germany and lead investigator for the study. “With botulinum toxin manufacturers each having unique definitions of a unit, aesthetic practitioners should be vigilant in adopting the treatment protocol set by the respective manufacturer and not translating previous experience with one toxin to another.”
 In the trial, 224 patients with moderate or severe glabellar lines were randomised to receive a single treatment cycle of either VISTABEL® (20 Allergan Units) or Bocouture® (30 Merz Units).  At day 28, the number of responders in the VISTABEL® treatment group was 108 (96%), compared to 106 responders (95%) treated with the Merz toxin.  The response rate for the two treatment groups was statistically equivalent, demonstrating that 20 Units of VISTABEL® is as effective as 30 Units of the Merz toxin at the end of four weeks. Beyond four weeks, statistical equivalence was not shown, and treatment responses showed a numerical trend in favour of the patients treated with 20 units of VISTABEL® at all time points, out to 16 weeks (112 days).  Furthermore, patient-reported assessments of response using the Facial Wrinkle Scale confirmed the injector findings throughout the 16 weeks of the study, with comparative benefit observed with both treatments.  In total, 42 adverse events were reported – three were considered treatment-related (one in the VISTABEL® group, two in the Merz toxin group).  Most adverse events were mild, no serious adverse events were reported, and no patients were withdrawn from the study due to adverse events.
“Allergan has an extensive and deep understanding of the science behind botulinum toxins based on more than 21 years of research and development.  As with all biological products, no two manufacturered botulinum toxin products are the same,” said Dr Antony Fulford-Smith, VP and head of medical affairs at Allergan in Europe, Africa and the Middle East. “We are pleased to see further evidence for the efficacy of VISTABEL® and consider that this study provides further clarity that VISTABEL® and the Merz unit doses are not interchangeable in clinical practice.”

Comments

Log-in to post a comment

  • Dr Aase E Larsen 30 Oct 2018 / 8:19 AM

    Botox & vistabel has complexing proteins and is a heavier molecule than Xeomin - effect is different as well